DTI officials ignoring CSC re customer’s complaint vs. DTI?
I have a copies of two letters, both identified as from a source identified as Maria Luisa Salonga Agamata Director IV Public Assistance and Information Office of the CSC. The earlier letter was dated October 4, 2010 and was addressed to DTI Secretary Gregory L. Domingo regarding three of my letters sent to said DTI by registered mail but as of October 4, 2010 said DTI had not acknowledged receipt of said letters. Since, by December 12, 2010, no person from DTI had provided me with a reply to said Agamata’s October 4, 20 letter to said DTI Secretary, I informed the CSC about the my non receipt of a reply from said DTI re said Agamata’s October letter.





Dra. Vicky Belo ignored DTI letter?
I have a letter from a source identified as Victorio Mario A. Dimagiba Director Bureau of Trade Regulation and Consumer
Protection, 2/F Trade & Industry Building, 361 Senator Gil Puyat Avenue, Makati, and dated 19 October 2010 and addressed to
said Belo. Said letter contains the words: “...we refer to you for appropriate action (my) . . . attached complaint letter
of Mr. . . . He . . .in his letter. . . claimed that he has requested for information of a product which he sent through
registered mail and confirmed received by your agent months ago. However, to date . . . he has not yet been provided any
reply on the requested information.Kindly give this matter your most preferential attention and please inform the
complainant of the action to be taken by your office . . .” Up to March 14, 2011, neither said Belo or her agent has
provided me with a reply to said DTI letter.



Lax security on January 11, 2011, at entrance to Glorietta, Ayala Center, Makati
A guard, at a street level entrance to said building: didn’t inspect my luggage; didn’t subject said luggage to scanning
with metal detector; didn’t have a bomb sniffing animal smell said luggage. Said luggage was large enough to contain
grenades. Said security lapse occurred at the Glorietta entry point nearest the Mercury Drug store branch at said building.
After entering said building at said location, I bought a product at said drug store and was issued a Mercury Drug official
receipt numbered 941205.

security lapses and violations of R.A. 9257
at SM Mall of Asia, Pasay City
On February 19, 2011, I witnessed lax security and violations of R.A. 9257 at the SM Mall of Asia. Said area was
under the jurisdiction of Pasay City Mayor Calixto. Guards at two entrances
to said mall; didn’t inspect my luggage; didn’t use a metal detector to scan my luggage; didn’t have a bomb sniffing dog
smell said luggage. Said luggage was large enough to contain grenades. Several stores, in said mall,which are supposed to
obey the implementing rules and regulations of R.A. 9257, didn’t prominently display posters, etc. that generated public
awareness of the rights and privileges of senior citizens.. One of said stores was identified as Globe Broadband, Inc. I
have proof of purchase issued by said store.Rule IX Article 11 of Republic Act No. 9257 contains the following statement:
"It shall be the responsibility of the municipality/city through the Mayor to require all establishments covered by the Act
to prominently display posters, stickers, and other notices that will generate public awareness of the rights and
privileges of senior citizens. Based on said rule, it is the responsibility of Pasay City Mayor Calixto to require said
stores to prominently display said posters, etc.

Web sites with free useful information:


Eat for a Healthy Heart
http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm199058.htm

http://www.fda.gov/Safety/Recalls/default.htm
FDA gov recalls
03/05/2011 Smith and Nephew IV PREP Antiseptic Wipes Potential contamination with Bacillus cereus Smith & Nephew, Inc.
03/04/2011 Skippy Peanut Butter Salmonella Unilever
03/04/2011 Golden Dipt Tempura Seafood Batter Mix Undeclared Milk McCormick & Company, Incorporated
03/03/2011 Sunripe, George Packing, Others Hazelnut and mixed nut products Escherichia coli O157:H7 DeFranco and Sons
03/03/2011 Teavana Peppermint Organic Herbal Tea Salmonella Teavana Corporation
03/02/2011 Gourmet Family Large Mouth Smelt Komochi Shishamo Clostridium botulinum Daiei Trading Company, Inc.
03/02/2011 Garden of Life Vitamin Code Raw Vitamin C Undeclared soy proteins Garden of Life, LLC
02/28/2011 Wellness Canned Cat Food Inadequate Levels of Thiamine WellPet, LLC
02/25/2011 E&J E&J VSOP and E&J XO Gift Sets Elevated Levels of Lead E&J Brandy
02/24/2011 Tfarms, Raleys, Signature Cafe Broccoli items Listeria monocytogenes Taylor Farms Pacific


FDA prompts removal of unapproved drugs from market
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm245048.htm
FDA NEWS RELEASE

For Immediate Release: March 2, 2011
Media Inquiries: Shelly Burgess, 301-796-4651; shelly.burgess@fda.hhs.gov
Consumer Inquiries: 888-INFO-FDA


FDA prompts removal of unapproved drugs from market
Class action is part of FDA’s Unapproved Drugs Initiative

The U.S. Food and Drug Administration today took action against companies that manufacture, distribute, or market certain unapproved prescription oral cough, cold, and allergy products. The affected products cannot be legally marketed in the United States.

Unapproved prescription cough, cold, and allergy drug products have not been evaluated by the FDA for safety, effectiveness, and quality. People may be at greater risk when using these products than when using FDA-approved prescription drugs or drugs that are appropriately marketed over-the-counter (OTC).

Many health care providers are unaware of the unapproved status of drugs and have continued to unknowingly prescribe them because the drugs’ labels do not disclose that they lack FDA approval.

“Removing these unapproved products from the market will reduce potential risks to consumers,” said Deborah Autor, director of the Office of Compliance in the FDA’s Center for Drug Evaluation and Research. “There are many FDA-approved prescription products, as well as appropriately marketed over-the-counter products, available to treat cough, cold, and allergy symptoms; so, we expect little or no negative impact on consumers from the removal of these unapproved products.”

Companies that have previously listed products subject to today’s action with FDA are expected to stop manufacturing them within 90 days and stop shipping the products within 180 days. Companies that have not previously listed products subject to today’s action with FDA are expected to stop manufacturing and shipping their products immediately.

Given that so many cough, cold, and allergy drug products exist that are FDA-approved prescription products or are appropriately marketed OTC, taking an unapproved prescription product is an unnecessary risk.

Consumers who believe they are taking an unapproved prescription cough, cold, or allergy product should contact their health care provider to discuss alternatives.

This is the 17th action on a drug class as part of FDA's Unapproved Drugs Initiative, which began in June 2006. The initiative is the agency’s risk-based enforcement approach to efficiently and rationally bring all unapproved new drugs into the approval process. One of the goals of the initiative is to reduce consumer exposure to drugs that are not proven safe, effective, and of high quality.

Consumers and health care professionals are encouraged to report adverse side effects or medication errors from the use of unapproved prescription cough, cold, and allergy products to the FDA's MedWatch Adverse Event Reporting program at www.fda.gov/MedWatch or by calling 800-332-1088.

Unapproved Prescription Cough, Cold, and Allergy Products Federal Register Notice (PDF)
List of Unapproved Prescription Cough, Cold, and Allergy Drug Products Affected by Today’s Action, Based on Firm's Listing with FDA
Unapproved Drugs Enforcement Actions (By Drug Class)
Consumer Health Update: FDA Intends to Remove Unapproved Drugs from the Market (March 2, 2011)


New Steps Aimed at Cutting Risks from Acetaminophen
http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm239747.htm